Treatment with Axatilimab in Chronic GVHD: How it Works and Insights into Treatment Efficacy

MaaT013 showed positive results in the phase 3 ARES trial, meeting its primary endpoint of GI-ORR at day 28 in patients with third-line GI-aGVHD.

An oncology nurse discusses 4 common barriers certain patient populations face when it comes to oncology clinical trials, and what clinicians can do to mitigate these disparities.

The FDA approved axatilimab for adults and children with chronic graft-vs-host disease whose disease progressed after 2 or more lines of systemic therapy.

The biologics license application that was resubmitted for remestemcel-L has been accepted by the FDA for the potential treatment of children with steroid-refractory acute graft-vs-host-disease.

Taking mismatched unrelated donors into consideration may increase donor numbers, especially for patients with minority ancestry who are seeking hematopoietic cell transplantation.

Patients with chronic graft-vs-host disease treated with belumosudil experienced responses out to 3 years with no new safety signals.